Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) [clinicaltrials:NCT00171938]

Bio2RDF uri

Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) [clinicaltrials:NCT00171938]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00171938

Bio2RDF identifier

NCT00171938

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00171938

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00171938

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:26de85e6bd54583a3ade3b90c734be62

brief summary [clinicaltrials_vocabulary:brief-summary]

This is an open label c ...... ted for up to 12 months

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Open-label Trial of Imatinib M ...... rived Growth Factor Receptors)

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

PFS (progression free-survival), defined by the percentage of patients without evidence of progressive disease in 6 months [clinicaltrials_resource:bed7f7635045eaa4d8cb05534a949647]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

PFS (progression free-survival), defined by the percentage of patients without evidence of progressive disease in 6 months [clinicaltrials_resource:78dc6759383f82bf3b51128772b4b8e1]

PFS (progression free-survival), defined by the percentage of patients without evidence of progressive disease in 6 months [clinicaltrials_resource:c5d7e172c728ac5237ab77cdc8ebb783]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00171938 [clinicaltrials_resource:b5a670b01e955e2905a5493b272b591f]

enrollment [clinicaltrials_vocabulary:enrollment]

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

imatinib mesylate [clinicaltrials_resource:ae235f4a8f4ed283372337cb025b1429]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Mitogens [clinicaltrials_resource:2a529d3c4b469dec760d382bb10e5482]

Imatinib [clinicaltrials_resource:daa3ac9ba968405a1d6671857c44fe86]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Brain tumors

http://www.w3.org/2001/XMLSchema#string

Glioblastoma

http://www.w3.org/2001/XMLSchema#string

Imatinib

http://www.w3.org/2001/XMLSchema#string

PDGFR

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2009-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Novartis [clinicaltrials_resource:4b711ffdbe8af5c8f3f9c53da46d83fa]

location [clinicaltrials_vocabulary:location]

[clinicaltrials_resource:c2a1de8bec3c8d0bad352705f46d2b64]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00171938

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

Open-label Trial of Imatinib M ...... rived Growth Factor Receptors)

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

CSTI571BBR03

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Novartis [clinicaltrials_resource:6f2d4fc54fb25602a33e239b65a68c25]

overall status [clinicaltrials_vocabulary:overall-status]

Suspended [clinicaltrials_resource:8bf906833cc7aea8084f552217ed9c1d]

oversight [clinicaltrials_vocabulary:oversight]

Brazil: National Health Surveillance Agency [clinicaltrials_resource:973fcc9a4783a19496ebddec84efad8b]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

source [clinicaltrials_vocabulary:source]

Novartis [clinicaltrials_resource:4b711ffdbe8af5c8f3f9c53da46d83fa]

start date [clinicaltrials_vocabulary:start-date]

2004-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00171938 study design [clinicaltrials_resource:416a507d34e90195e02db0cbca339547]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00171938

verification date [clinicaltrials_vocabulary:verification-date]

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00171938

http://www.w3.org/2001/XMLSchema#string

title

Open-label Trial of Imatinib M ...... rived Growth Factor Receptors)

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Open-label Trial of Imatinib M ...... ) [clinicaltrials:NCT00171938]

@en